S1 registration statement of Kraig Biocraft Laboratories declared effective

NewsGuard 100/100 Score

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.

“After working on this for nearly nine months, we are very happy to announce that the SEC has informed the Company that its S1 registration is now effective”

"After working on this for nearly nine months, we are very happy to announce that the SEC has informed the Company that its S1 registration is now effective," said CEO Kim K. Thompson. "The S1 registration lays the foundation for our financing program over the next twenty four months. When we originally filed the S1 our legal advisors told us that we could expect a delay of at least forty five days. Those forty five days ultimately turned into almost nine months. While we have been pursuing this clearance our legal advisors informed us that the Company should limit its public communication to avoid the perception of any promotion. We want to thank all of our shareholders for their patience during this arduous process and we look forward to what we now believe will be a very successful year for Kraig Biocraft Laboratories."

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diet's role in fighting vitiligo highlighted in new research